ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,703,180 | -28.9% | 1,562,508 | +7.6% | 0.00% | 0.0% |
| Q2 2023 | $15,057,074 | +30.8% | 1,451,984 | +2.0% | 0.00% | 0.0% |
| Q1 2023 | $11,514,934 | -72.0% | 1,423,354 | -45.4% | 0.00% | 0.0% |
| Q4 2022 | $41,054,896 | +100.2% | 2,606,660 | +100.0% | 0.00% | 0.0% |
| Q3 2022 | $20,510,000 | +19.4% | 1,303,027 | +5.9% | 0.00% | 0.0% |
| Q2 2022 | $17,174,000 | -8.1% | 1,230,241 | +13.6% | 0.00% | 0.0% |
| Q1 2022 | $18,678,000 | +22.6% | 1,083,390 | +3.4% | 0.00% | 0.0% |
| Q4 2021 | $15,229,000 | -20.0% | 1,047,390 | -1.0% | 0.00% | 0.0% |
| Q3 2021 | $19,047,000 | +1.4% | 1,058,164 | -1.1% | 0.00% | 0.0% |
| Q2 2021 | $18,793,000 | +286.5% | 1,070,214 | +454.7% | 0.00% | – |
| Q1 2021 | $4,862,000 | +862.8% | 192,942 | +147.2% | 0.00% | – |
| Q4 2020 | $505,000 | +151.2% | 78,040 | 0.0% | 0.00% | – |
| Q3 2020 | $201,000 | +59.5% | 78,040 | 0.0% | 0.00% | – |
| Q2 2020 | $126,000 | -81.8% | 78,040 | -88.3% | 0.00% | – |
| Q1 2020 | $694,000 | -50.2% | 667,188 | -9.5% | 0.00% | – |
| Q4 2019 | $1,394,000 | +73.6% | 737,398 | -0.8% | 0.00% | – |
| Q3 2019 | $803,000 | -39.5% | 743,330 | +22.5% | 0.00% | – |
| Q2 2019 | $1,328,000 | -66.2% | 606,579 | -7.4% | 0.00% | – |
| Q1 2019 | $3,925,000 | -27.7% | 655,342 | -10.8% | 0.00% | – |
| Q4 2018 | $5,429,000 | -38.5% | 734,683 | +20.8% | 0.00% | -100.0% |
| Q3 2018 | $8,832,000 | -20.6% | 608,099 | +9.2% | 0.00% | 0.0% |
| Q2 2018 | $11,120,000 | +12.7% | 556,645 | -1.2% | 0.00% | 0.0% |
| Q1 2018 | $9,867,000 | -18.3% | 563,162 | +15.1% | 0.00% | 0.0% |
| Q4 2017 | $12,070,000 | -6.9% | 489,424 | -2.6% | 0.00% | 0.0% |
| Q3 2017 | $12,962,000 | +44.5% | 502,241 | +51.8% | 0.00% | 0.0% |
| Q2 2017 | $8,971,000 | +52.0% | 330,755 | +67.1% | 0.00% | 0.0% |
| Q1 2017 | $5,902,000 | +27.4% | 197,889 | +16.0% | 0.00% | – |
| Q4 2016 | $4,631,000 | +36.9% | 170,630 | +29.2% | 0.00% | – |
| Q3 2016 | $3,383,000 | +52.6% | 132,060 | +10.0% | 0.00% | – |
| Q2 2016 | $2,217,000 | +60.8% | 120,010 | +64.8% | 0.00% | – |
| Q1 2016 | $1,379,000 | +14.7% | 72,831 | +63.1% | 0.00% | – |
| Q4 2015 | $1,202,000 | – | 44,653 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |